Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study

The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin an...

Full description

Bibliographic Details
Main Authors: V. A. Parfyonov, S. V. Verbitskaya
Format: Article
Language:Russian
Published: Remedium Group LLC 2014-12-01
Series:Медицинский совет
Subjects:
Online Access:https://www.med-sovet.pro/jour/article/view/560
id doaj-809afc9bf26a4114902e7ed083d61c31
record_format Article
spelling doaj-809afc9bf26a4114902e7ed083d61c312021-07-28T13:29:17ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-010561110.21518/2079-701X-2014-5-6-11560Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF studyV. A. Parfyonov0S. V. Verbitskaya1First Moscow State Medical University named after I.M. SechenovFirst Moscow State Medical University named after I.M. SechenovThe article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin and novel oral anticoagulants: inhibitor of coagulation factor Xa rivaroxaban, apixaban, and the direct thrombin inhibitor dabigatran. There are results of a ROCKET AF subanalysis which compared rivaroxaban and warfarin in patients with AF after IS or TIA. It is noted that widespread clinical use of oral anticoagulants for atrial fibrillation could result in a significant reduction of IS morbidity and mortality in this country.https://www.med-sovet.pro/jour/article/view/560вторичная профилактика ишемического инсультафибрилляция предсердийпероральные антикоагулянтыапиксабандабигатранривароксабансубанализ исследования rocket afsecondary prevention of ischemic strokeatrial fibrillationoral anticoagulantsapixabandabigatranrivaroxabanrocket af subanalysis
collection DOAJ
language Russian
format Article
sources DOAJ
author V. A. Parfyonov
S. V. Verbitskaya
spellingShingle V. A. Parfyonov
S. V. Verbitskaya
Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
Медицинский совет
вторичная профилактика ишемического инсульта
фибрилляция предсердий
пероральные антикоагулянты
апиксабан
дабигатран
ривароксабан
субанализ исследования rocket af
secondary prevention of ischemic stroke
atrial fibrillation
oral anticoagulants
apixaban
dabigatran
rivaroxaban
rocket af subanalysis
author_facet V. A. Parfyonov
S. V. Verbitskaya
author_sort V. A. Parfyonov
title Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
title_short Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
title_full Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
title_fullStr Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
title_full_unstemmed Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study
title_sort secondary ischemic stroke prevention in patients with atrial fibrillation: results of the rocket af study
publisher Remedium Group LLC
series Медицинский совет
issn 2079-701X
2658-5790
publishDate 2014-12-01
description The article tells about prevention of ischemic stroke (IS) in patients after IS or transient ischemic attack (TIA) against a background of non-valvular atrial fibrillation (AF). Anticoagulation therapy variants for secondary IS prevention in AF are evaluated, such as vitamin K antagonist warfarin and novel oral anticoagulants: inhibitor of coagulation factor Xa rivaroxaban, apixaban, and the direct thrombin inhibitor dabigatran. There are results of a ROCKET AF subanalysis which compared rivaroxaban and warfarin in patients with AF after IS or TIA. It is noted that widespread clinical use of oral anticoagulants for atrial fibrillation could result in a significant reduction of IS morbidity and mortality in this country.
topic вторичная профилактика ишемического инсульта
фибрилляция предсердий
пероральные антикоагулянты
апиксабан
дабигатран
ривароксабан
субанализ исследования rocket af
secondary prevention of ischemic stroke
atrial fibrillation
oral anticoagulants
apixaban
dabigatran
rivaroxaban
rocket af subanalysis
url https://www.med-sovet.pro/jour/article/view/560
work_keys_str_mv AT vaparfyonov secondaryischemicstrokepreventioninpatientswithatrialfibrillationresultsoftherocketafstudy
AT svverbitskaya secondaryischemicstrokepreventioninpatientswithatrialfibrillationresultsoftherocketafstudy
_version_ 1721274616018632704